ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.91 – $1.00
Volume15,911
Market cap$25M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$25.36M
Price / earnings
—
Price / book
1.94×
Price / sales
—
EV / sales
—
EV / EBITDA
-7.11×
Profitability
Earnings per share
-$0.04
Return on assets
-5.66%
Return on equity
-8.8%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
0.2×
Quick ratio
0.2×
Cash ratio
0×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$3M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ABVC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
—
$0
$0
$0
$1.97K
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
—
$0
$0
$0
$1.97K
Selling, general and administrative
$1.22M
$756.82K
$752K
—
$1.93M
$2.26M
$615.37K
$3.08M
Research and development
$18.04K
$22.71K
$33.1K
—
$29.89K
$33.28K
$28.86K
$31.98K
Total operating expenses
$1.24M
$779.53K
$1.57M
—
$1.96M
$2.29M
$693.01K
$706.53K
Operating income
-$1.24M
-$779.53K
-$1.57M
—
-$1.96M
-$2.29M
-$693.01K
-$704.56K
Interest expense
-$43.65K
-$42.32K
-$49.38K
—
-$30.96K
-$129.41K
-$222.97K
-$216.72K
Income before taxes
-$1.39M
-$810.48K
-$1.69M
—
-$2.08M
-$2.31M
-$944.19K
-$796.53K
Income taxes
$0
$0
$0
—
$527
$23.63K
$0
$0
Net income
-$1.39M
-$810.48K
-$1.69M
—
-$2.08M
-$2.33M
-$944.19K
-$796.53K
Net income attributable to common shareholders
$1.15M
-$736.93K
-$1.56M
—
-$2.04M
-$2.26M
-$842.08K
-$731.57K
EBITDA
-$1.23M
-$773.01K
-$1.57M
$5.79K
-$1.96M
-$2.29M
-$685.98K
-$694.14K
Basic earnings per share
$0.04
-$0.03
-$0.06
—
-$0.09
-$0.13
-$0.06
-$0.06
Diluted earnings per share
$0.04
-$0.03
-$0.06
—
-$0.09
-$0.13
-$0.06
-$0.06
Recent news
Company coverage with links to the original publishers.
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life.
FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation (FEYE) for the Company's Ophthalmology pipeline, which includes the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). This license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights.
FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. These results, including the financial statements included herein, can be found in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2024.
FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC’s botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.
Shares of Mobileye Global Inc. (NASDAQ: MBLY) fell sharply during Thursday’s session after the company issued preliminary FY23 financial results and initial 2024 guidance.
For the fourth quarter, the company expects revenue of $634 million-$638 million (vs. $636.39 million) and adjusted operating income of $241 million-$247 million. The company's previous implied guidance was $623 million-$648 million in revenue.
Wolfe Research analyst Shreyas Patil downgraded Mobileye Global from Outperform to Peer Perform.
Mobileye Global shares dipped 23.5% to $30.37 on Thursday.
Here are some other stocks moving in today's mid-day session.
Gainers
Minim, Inc. (NASDAQ: MINM) shares jumped 170.2% to $4.62.
Omega Therapeutics, Inc. (NASDAQ: OMGA) gained 92.7% to $5.26 after Novo Nordisk entered into a research collaboration with the company.
Avenue Therapeutics, Inc. (NASDAQ: ATXI) shares climbed 65.8% to $0.2920 after the company announced it reached a final agreement with the FDA for the Phase 3 safety study for IV tramadol.
Jeffs' Brands Ltd(NASDAQ: JFBR) gained 40% to $4.41 after surging 25% on Wednesday. Jeffs' Brands, last month, signed non-binding letters of intent with Sky Growth Partners to invest in a DLP laser-based system for counter-drone solutions and laser-based wireless charging technology.
Mobix Labs, Inc. (NASDAQ: MOBX) gained 33.3% to $4.00. Mobix Labs was awarded 15-month contract to supply EMI filtered connectors as part of US Army's M-1 Abrams Tank Program.
ATIF Holdings Limited (NASDAQ: ATIF) jumped 30.6% to $1.32.
Adicet Bio, Inc. (NASDAQ: ACET) surged 26.1% to $2.22. Adicet Bio issued corporate updates and highlighted upcoming priorities for its pipeline programs in 2024.
Smart for Life, Inc. (NASDAQ:
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.